A.V. Mikhailov

A.V. Mikhailov

Auto-generated profile, based on publicly available information

A.V. Mikhailov

Joint-Stock Company «Medicine

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026 in Russian Journal of Stomatology
Verified
Journal Article
Closed access
AMA.O. Mikiya
A.O. Mikiya
NGN.A. Guseynov
N.A. Guseynov
ICIgor Cherkesov
Igor Cherkesov
AMA.V. Mikhailov
A.V. Mikhailov
AOA.A. Orlov
A.A. Orlov
ABA.M. Belotskaya
A.M. Belotskaya
Objective. To analyze current evidence on the use of botulinum toxin type A (BoNT-A) for optimizing neuromuscular adaptation and preventing complications after orthognathic surgery. Materials and methods. A literature search was conducted in PubMed, Scopus, and Elibrary (2017—2026). Randomized controlled trials, systematic reviews, and meta-analyses on BoNT-A effects on masticatory muscles in the maxillofacial area were included. Results. Direct clinical evidence is limited: Shin (2018) RCT showed that BoNT-A injection into the masseter muscles reduced plate fracture rate (2/16 vs. 8/16, p=0.031). Ban (2023) reported stable occlusion at 9 months after BoNT-A into the anterior belly of the digastric muscle (n=5). Systematic reviews confirm reversible masticatory muscle atrophy, decreased bite force, and EMG activity. Safety profile is favorable, with transient local adverse effects. A marked placebo effect has been demonstrated. Conclusion. BoNT-A may effectively reduce loading on osteosynthesis sites and prevent relapse, but existing studies have small sample sizes, short follow-up, and lack standardization. Large placebo-controlled trials with long-term follow-up are needed.